Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8296045 | 0.89 | HTR2B (0.73) | HTR2BALDH1A1LMNAMAPTHTT | |
| SCHEMBL993093 | 0.88 | HTR2B (0.55) | HTR2BHRH1CHRNA7KCNH2MAPT | |
| SCHEMBL14916479 | 0.85 | KCNH2 (0.51) | HTR2BHRH1CHRNA7KCNH2ALDH1A1 | |
| SCHEMBL28050009 | 0.85 | HTR2B (0.49) | HTR2BHRH1CHRNA7KCNH2PKM | |
| SCHEMBL28562183 | 0.85 | HRH1 (0.49) | HTR2BHRH1CHRNA7KCNH2MAPT | |
| SCHEMBL21815504 | 0.82 | HTR2B (0.47) | HTR2BHRH1CHRNA7KCNH2PKM | |
| SCHEMBL662101 | 0.82 | PARP1 (0.64) | HTR2BCHRNA7KCNH2ALDH1A1NPSR1 | |
| SCHEMBL9397015 | 0.80 | HRH1 (0.51) | HTR2BHRH1CHRNA7KCNH2SIGMAR1 | |
| SCHEMBL28562199 | 0.78 | POLB (0.52) | HTR2BCHRNA7KCNH2ALDH1A1MAPT | |
| SCHEMBL17888861 | 0.78 | HTR2B (0.62) | HTR2BCHRNA7PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009636-A1 | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KP) | 2011-01-13 | — | — | US | disclosed |
| EP-2240464-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | Yuhan Corporation (KR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102155-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2009-08-20 | — | — | WO | disclosed |
| EP-0580541-B1 | Piperidine derivatives of benzimidazole as antihistaminic and antiallergic agents | ESPANOLA PROD QUIMICOS (ES) | 1999-10-06 | — | — | EP | disclosed |
| US-5322850-A | Antiallergic piperidine derivatives of benzimidazole | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1994-06-21 | — | — | US | disclosed |
| EP-0580541-A1 | New piperidine derivatives of benzimidazole as antihistanminic and antiallergic agents | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009636-A1 | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH4, HCAR2, HRH1 | HTR2B 63/4885HRH1 3/4885CHRNA7 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.